The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | New therapies for MM
The field of multiple myeloma (MM) has seen an influx of exciting new therapies. Here, Guy Pratt, MD, FRCP, FRCPath, of the University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, discusses a variety of them at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. He gives an overview of the drugs he thinks have the greatest potential to transform the field. These include: lenalidomide, which is being used for maintenance and continuous therapy; carfilzomib, a next-generation proteasome inhibitor; and daratumamab, a monoclonal antibody therapy for the relapsed setting. Dr Pratt also discusses the potential to combine these new therapies to achieve even better responses.
